ReviewCurrent rheumatology reports2024
Recent Updates on the Pathogenesis of Inflammatory Myopathies.
Review in Current rheumatology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.The Cochrane database of systematic reviews · 2025Pooled it
- Emerging therapies in idiopathic inflammatory myopathies.Journal of neuromuscular diseases · 2026Review
- Optimizing line blot assays: impact of band intensity adjustment on diagnostic performance in myositis autoantibodies testing.Clinical rheumatology · 2026Article
- Association of malnutrition with in-hospital outcomes among patients hospitalized with dermatomyositis or polymyositis.Clinical rheumatology · 2026Article
- Quantitative Muscle Magnetic Resonance Imaging Demonstrates Resolution of Muscle Edema in Refractory Dermatomyositis: A Post Hoc Analysis of a Proof-of-Concept Clinical Trial of Tofacitinib.ACR open rheumatology · 2026Article
- Dermatomyositis: Prevalence, Clinical Spectrum, Diagnostic Approach, and Management Strategies.Archives of internal medicine research · 2026Article
- [Rheumatic disease spectrum and immunological profile of anti-PM/Scl antibodies in idiopathic inflammatory myopathies].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025Article
- Immunopathogenic Mechanisms in Connective Tissue Disease-Associated Interstitial Lung Disease: Incessant Loop of Immunity to Fibrosis.International journal of molecular sciences · 2025Review
- Distinct cytokine and cytokine receptor expression patterns characterize different forms of myositis.Rheumatology (Oxford, England) · 2025Article
- [Experiences after CD19-CAR T-cell therapy in non-SLE connective tissue diseases].Zeitschrift fur Rheumatologie · 2025Review
- Clinical characteristics of Hispanic patients with anti-SAE dermatomyositis.Clinical rheumatology · 2025Article
- Epidemiology of myositis.Current opinion in rheumatology · 2025Review
- Paraneoplastic Dermatoses: A Clue for Underlying Malignancies.Journal of clinical medicine · 2025Review
- The role of monocytes and macrophages in idiopathic inflammatory myopathies: insights into pathogenesis and potential targets.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to provide a comprehensive and updated overview of autoimmune myopathies, with a special focus on the latest advancements in understanding the role of autoantibodies. We will begin by examining the risk factors and triggers associated with myositis. Next, we will delve into recent research on how autoantibodies contribute to disease pathogenesis. Finally, we will explore the latest innovations in treatment strategies and their implications for our understanding of myositis pathogenesis. RECENT
findingsRecent research has revealed that myositis-specific autoantibodies can infiltrate muscle cells and disrupt the function of their target autoantigens, playing a crucial role in disease pathogenesis. Significant advances in treatment include CD19 CAR-T cell therapy, JAK-STAT inhibitors, and novel strategies targeting the type 1 interferon pathway in dermatomyositis. Additionally, the ineffectiveness of complement inhibitors in treating immune-mediated necrotizing myositis has challenged established views on disease mechanisms. Autoimmune myopathies are a collection of disorders significantly influenced by specific autoantibodies that drive disease pathogenesis. This review highlights the critical role of autoantibody research in deepening our understanding of these conditions and discusses recent therapeutic advancements targeting key pathogenic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.